Company
Apotex
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
15
10 still marketed
Novel approvals
4
Approvals since 2021
7
Originals and new uses
Phase 3 trials
3
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Evdi approved May 1, 2026
- Caldolor new use Jan 23, 2026
- Acetadote new use OrphanNov 26, 2024
- Ivra approved Aug 18, 2023
- Caldolor new use May 11, 2023
- Bendamustine Hydrochloride approved Dec 7, 2022
- Caldolor new use Nov 19, 2021
- Vibativ new use May 6, 2016
- Caldolor new use Nov 20, 2015
- Docetaxel approved Jan 11, 2012
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (10)
Newest FDA action first.
- Paxil Paroxetine Hydrochloride · 1992
- Paxil Cr Paroxetine Hydrochloride · 1999
- Evdi Trabectedin · 2026
- Caldolor Ibuprofen · 2009
- Acetadote Acetylcysteine · 2004
- Sancuso Granisetron · 2008
- Ivra Melphalan Hydrochloride · 2023
- Bendamustine Hydrochloride Bendamustine Hydrochloride · 2022
- Vibativ Telavancin Hydrochloride · 2009
- Vaprisol In 5% Dextrose In Plastic Container Conivaptan Hydrochloride · 2005
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.